Novel Platelet-Like PLGA-PSP Nanoparticles Based on Platelet-Specific Peptides Alleviated Traumatic Hemorrhage

Area of Science:

• Biomaterials Science
• Nanotechnology
• Hemostasis Research

Background:

• Platelets are vital for coagulation, but supply shortages pose clinical challenges.
• Traumatic hemorrhage necessitates effective and safe platelet substitutes.
• Current platelet concentrate limitations drive the search for alternatives.

Purpose of the Study:

• To synthesize and evaluate novel platelet-like nanoparticles (PLGA-PSP) as a substitute for platelet concentrates.
• To assess the biosafety and hemostatic efficacy of PLGA-PSP nanoparticles.
• To investigate the potential of PLGA-PSP nanoparticles in managing traumatic hemorrhage.

Main Methods:

• Synthesized PLGA-PSP nanoparticles by coupling platelet-specific peptides to PLGA-PEG nanoparticles.
• Assessed nanoparticle biosafety and in vitro effects on platelet adhesion, aggregation, and activation.
• Evaluated hemostatic efficacy in mouse models of tail vein, liver, and femoral artery hemorrhage.

Main Results:

• Successfully synthesized non-toxic PLGA-PSP nanoparticles with specific hemostatic ability.
• Demonstrated significant induction of platelet adhesion and aggregation without adverse activation.
• Effectively reduced bleeding time and blood loss in various hemorrhage models.

Conclusions:

• PLGA-PSP nanoparticles offer a promising therapeutic strategy for rapid hemostasis.
• The developed nanoparticles exhibit both biosafety and efficacy for traumatic hemorrhage.
• This novel approach could overcome limitations associated with traditional platelet transfusions.